A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer

Abstract Background Results from randomized phase III trials have shown that thrice-weekly docetaxel added to androgen-deprivation therapy (ADT) has a significant impact on the survival of patients with metastatic castration-naïve prostate cancer (mCNPC) and established early chemotherapy as part of...

Full description

Bibliographic Details
Main Authors: Sang Eun Yoon, Youjin Kim, Jangho Cho, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byoung Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Su Jin Lee, Se Hoon Park
Format: Article
Language:English
Published: BMC 2019-05-01
Series:BMC Urology
Subjects:
Castration-naïve prostate cancer
Docetaxel
Biweekly
Online Access:http://link.springer.com/article/10.1186/s12894-019-0463-7

Internet

http://link.springer.com/article/10.1186/s12894-019-0463-7

Similar Items